Gender |
Male, N (%) | 32 (61.5) | 20 (41.7) |
Female, N (%) | 20 (38.5) | 28 (58.3) |
Total | 52 | 48 |
Age at diagnosis, median (range) | 30 (7–64) | 34 (8–74) |
Age at inclusion, median (range) | 42 (18–68) | 48 (19–95) |
Disease duration (year), median (range) | 8 (0–32) | 8 (0–52) |
Patients at baseline | Web N=51 | Control N=41 |
Gender |
Male, N (%) | 31 (60.8) | 17 (41.5) |
Female, N (%) | 20 (39.2) | 24 (58.5) |
Total | 51 | 41 |
Age at diagnosis, median (range) | 29 (7–64) | 34 (8–57) |
Age at inclusion, median (range) | 41 (18–66) | 46 (19–65) |
Disease duration (years), median (range) | 8 (0–32) | 8 (1–52) |
Disease extension, N (%) |
Proctitis | 20 (39.2) | 21 (51.2) |
Left sided | 18 (35.5) | 10 (24.4) |
Pancolitis | 13 (25.5) | 10 (24.4) |
SCCAI, median (range) | 1 (0–9) | 2 (0–7) |
5-ASA treatment systemic, N (%) |
Asacol | 31 (60.8) | 20 (48.8) |
Pentasa | 12 (23.5) | 7 (17.1) |
Dipentum | 2 (3.9) | 1 (2.4) |
Salazopyrin | 1 (2.0) | 8 (19.5) |
Mezavant | 0 (0) | 1 (2.4) |
None | 5 (9.8) | 4 (9.8) |
Suppositories, N (%) |
Asacol | 2 (3.9) | 2 (4.9) |
Pentasa | 2 (3.9) | 4 (9.8) |
Salofalk | 1 (2.0) | 0 (0) |
None | 46 (90.2) | 35 (85.4) |
Enema/foam |
Salofalk | 4 (7.8) | 1 (2.4) |
Pentasa | 0 (0) | 0 (0) |
Colifoam | 6 (11.8) | 6 (14.6) |
Pred-Clysma | 1 (2.0) | 1 (2.4) |
None | 40 (78.4) | 33 (80.5) |
BMI, median (range) | 25 (19–39) | 27 (19–41) |
Smoking (%) |
Non-smoker | 25 (49.0) | 22 (53.7) |
Active smoker | 11 (21.6) | 7 (17.1) |
Ex-smoker | 15 (29.4) | 12 (29.3) |
Marital status (%) |
Married | 32 (62.7) | 26 (63.4) |
Single | 19 (37.3) | 15 (36.6) |
Education (%) |
Academic | 9 (17.6) | 8 (19.5) |
Other education | 32 (62.7) | 29 (70.7) |
During education | 10 (19.6) | 4 (9.8) |
Occupation (%) |
Paid | 41 (80.4) | 29 (70.7) |
Unpaid | 8 (15.7) | 7 (17.1) |
Support | 2 (3.9) | 4 (9.8) |
Pensioner | 0 (0) | 1 (2.4) |